About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic
obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary
Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe
emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received
FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough
device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global
treatment guidelines and is widely considered a standard of care treatment option for improving breathing,
activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves
and the company, please visit www.Pulmonx.com.

Speak to a Zephyr Valve Representative: https://pulmonx.com/speak-to-a-zephyr-valve-representative/


The Zephyr Endobronchial Valve System – Product Information

Clinical Data Summary – Zephyr Valve

Patient Selection Guidance – Zephyr Valve

Case Study – 73 Year Old Male – Zephyr Valve

Case Study – 62 Year Old Female – Zephyr Valve